FOLD - Amicus Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
11.42
+0.21 (+1.87%)
At close: 4:00PM EST

11.42 0.00 (0.00%)
After hours: 4:48PM EST

Stock chart is not supported by your current browser
Previous Close11.21
Open11.27
Bid11.21 x 4000
Ask11.88 x 28000
Day's Range11.20 - 11.75
52 Week Range8.27 - 17.62
Volume3,169,376
Avg. Volume2,680,082
Market Cap2.488B
Beta (3Y Monthly)2.14
PE Ratio (TTM)N/A
EPS (TTM)-1.89
Earnings DateFeb 28, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.70
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    New Research Coverage Highlights Amicus Therapeutics, Clovis Oncology, YRC Worldwide, FORTERRA INC, Shenandoah Telecommunications, and Basic Energy Services — Consolidated Revenues, Company Growth, and Expectations for 2019

    NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire3 days ago

    Amicus Therapeutics to Announce Full-Year 2018 Financial Results on February 28, 2019

    CRANBURY, N.J., Feb. 12, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February.

  • Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
    Zacks4 days ago

    Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

    Zoetis Inc. (ZTS) is gearing up to report fourth-quarter 2018 results. The company continues to strengthen its diverse product portfolio through lifecycle innovations, strong customer relationships, and access to new markets and technologies.

  • GlobeNewswire10 days ago

    Amicus Therapeutics Announces Positive data in Pompe Disease Phase 1/2 Study for Up to 24 Months at 15th Annual WORLDSymposium™

    Amicus Therapeutics (FOLD) today announced additional positive results from a global Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in patients with Pompe disease, an inherited lysosomal storage disorder caused by an enzyme deficiency that leads to accumulation of glycogen (disease substrate) in cells. Patients treated with AT-GAA for up to 24 months showed improvements in six-minute walk test (6MWT) distance and other measures of motor function and muscle strength, stability or increases in forced vital capacity (FVC), and durable reductions in biomarkers of muscle damage and disease substrate. An additional poster2 with detailed results for the non-ambulatory cohort in the ATB200-02 study is also part of this afternoon’s poster session.

  • TheStreet.com11 days ago

    2 Small-Cap Stocks That Are Still a Bargain

    The biotech sector, home builders and small-caps overall were some of the strongest performers in the market last month. While not as cheap as they were to begin the year, there are a bevy of small- and mid-cap stocks that still look like they could rally further. With a market cap just over $2 billion, I would not be surprised to see Amicus acquired by a larger player at some point.

  • ACCESSWIRE18 days ago

    Today's Research Reports on Trending Tickers: Amicus Therapeutics and ACADIA Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / January 28, 2019 / U.S. equities closed higher on Friday as companies continue to report upbeat earnings and Trump and the Democrats agreed to reopen the government until Feb. ...

  • Amicus (FOLD) Boasts Strong Pipeline Amid Stiff Competition
    Zacks22 days ago

    Amicus (FOLD) Boasts Strong Pipeline Amid Stiff Competition

    Amicus (FOLD) is well placed after the United States approved its only marketed drug, Galafold, and the company added 14 new gene therapy programs to its pipeline for rare metabolic diseases.

  • GlobeNewswire28 days ago

    Amicus Therapeutics Announces Presentations and Posters at 15th Annual WORLDSymposium™ 2019

    CRANBURY, N.J., Jan. 18, 2019 -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Amicus Therapeutics and Sage Therapeutics

    NEW YORK, NY / ACCESSWIRE / January 16, 2019 /U.S. markets rose on Tuesday as Netflix helped push the tech sector higher after announcing it would raise the price of its monthly membership. Tech giants ...

  • Is Amicus Therapeutics' Sharp Reversal Warranted?
    Motley Foollast month

    Is Amicus Therapeutics' Sharp Reversal Warranted?

    Amicus' shares crumbled with the broader market's decline last month, but the biotech has staged a stunning rally during the first few weeks of trading in 2019.

  • GlobeNewswirelast month

    Research Report Identifies FedEx, Amicus Therapeutics, National HealthCare, Allegion, Horizon Global, and PICO with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Jan. 10, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswirelast month

    Amicus Therapeutics Provides Full-Year 2019 Strategic Outlook and Financial Guidance

    CRANBURY, N.J., Jan. 07, 2019 (GLOBE NEWSWIRE) --  Amicus Therapeutics (FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today provided unaudited preliminary Galafold revenue for the full-year 2018 and introduced its full-year 2019 strategic outlook and financial guidance. Pipeline expanded to include 14 new gene therapy programs, including two clinical programs in Batten disease, exceeding target of least one new clinical program in 2019.

  • GlobeNewswirelast month

    Amicus Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

    CRANBURY, N.J., Jan. 03, 2019 -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate.

  • GlobeNewswirelast month

    Amicus Therapeutics Announces Phase 1/2 Study of Gene Therapy for CLN3 Batten Disease

    Amicus Therapeutics (FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced the initiation of a Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of adeno-associated virus serotype 9 AAV9-CLN3 (AAV9-CLN3) gene therapy in children with CLN3 Batten disease. Batten disease is the common name for a broad class of rare, fatal, inherited disorders of the nervous system also known as neuronal ceroid lipofuscinoses, or NCLs. This first in human study of an investigational gene therapy in CLN3 Batten disease, a life-threatening genetic neurologic disorder that typically begins in early childhood and results in premature death, is currently being conducted at Nationwide Children’s Hospital (Columbus, Ohio).

  • How Are Sangamo Therapeutics’ Earnings and Expenses Trending?
    Market Realistlast month

    How Are Sangamo Therapeutics’ Earnings and Expenses Trending?

    Who Is Eyeing Sangamo Therapeutics Now?(Continued from Prior Part)Earnings trends In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.

  • A Financial Overview of Vanda Pharmaceuticals in December
    Market Realist2 months ago

    A Financial Overview of Vanda Pharmaceuticals in December

    In the first nine months of 2018, Vanda Pharmaceuticals’ (VNDA) net revenues grew ~16% YoY to reach $140.1 million from $120.8 million. In the third quarter, the company’s net revenues amounted to $49.1 million, reflecting ~19% YoY growth. Wall Street analysts estimate that Vanda Pharmaceuticals will generate revenues of $191.7 million in fiscal 2018.

  • Vanda Pharmaceuticals: Recent Developments and Analyst Ratings
    Market Realist2 months ago

    Vanda Pharmaceuticals: Recent Developments and Analyst Ratings

    On December 21, Vanda Pharmaceuticals (VNDA) stock closed at $24.00, which is a ~1.64% decline from its prior close of $24.40 on December 20, 2018. Vanda Pharmaceuticals stock price grew from $15.20 at the close of market on December 29, 2017, to $24.00 on December 21, 2018, reflecting ~58% YTD growth.

  • GlobeNewswire2 months ago

    Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease

    CRANBURY, N.J., Dec. 20, 2018 (GLOBE NEWSWIRE) --  Amicus Therapeutics (FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced the dosing of the first patient in a global phase 3 clinical study (ATB200-03, or PROPEL) of AT-GAA in adult patients with late onset Pompe disease. PROPEL is a 52-week, double-blind randomized study designed to assess the efficacy, safety and tolerability of AT-GAA compared to the current standard of care, alglucosidase alfa, an enzyme replacement therapy (ERT). All participants randomized to AT-GAA in the PROPEL study will receive drug manufactured at the 1000L scale intended for clinical and commercial supply.

  • GlobeNewswire2 months ago

    Amicus Therapeutics Announces Executive Team Updates

    Amicus Therapeutics (FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced that Daphne Quimi will be promoted to Chief Financial Officer, effective January 1, 2019. Ms. Quimi has been on the finance senior leadership team at Amicus for 11 years, having served as the Corporate Controller and most recently as Senior Vice President, Finance and Administration.

  • Simply Wall St.2 months ago

    Should You Worry About Amicus Therapeutics, Inc.’s (NASDAQ:FOLD) CEO Pay?

    John Crowley has been the CEO of Amicus Therapeutics, Inc. (NASDAQ:FOLD) since 2011. First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look at Read More...

  • GlobeNewswire2 months ago

    Amicus Therapeutics Awarded United Kingdom Prix Galien Medal for Galafold® (Migalastat)

    Amicus Therapeutics (FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced that Galafold® (migalastat) was awarded the 2018 UK Prix Galien Medal for Innovative Product. John F. Crowley, Chairman and Chief Exeutive Officer of Amicus Therapeutics, Inc., stated, “We are honored to receive the prestigious UK Prix Galien medal for Galafold, the first ever orphan drug to win in the Innovative Product category.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Immunomedics and Amicus Therapeutics

    NEW YORK, NY / ACCESSWIRE / December 11, 2018 / Wall Street bounced on Monday as optimism outweighed earlier losses caused by the U.S. - China trade dispute. Analysts expect the Federal Reserve to raise ...

  • Amicus Therapeutics, Inc. (FOLD) Hedge Funds Are Snapping Up
    Insider Monkey2 months ago

    Amicus Therapeutics, Inc. (FOLD) Hedge Funds Are Snapping Up

    The fourth quarter was a rough one for most investors, as fears of a rising interest rate environment in the U.S, a trade war with China, and a more or less stagnant Europe, weighed heavily on the minds of investors. Both the S&P 500 and Russell 2000 sank as a result, with the Russell 2000, […]

  • ACCESSWIRE3 months ago

    Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Amicus Therapeutics

    NEW YORK, NY / ACCESSWIRE / November 29, 2018 / Wall Street closed up on Wednesday as dovish comments made by Federal Reserve Chairman Jerome Powell boosted investor optimism. According to the Chairman, Jerome Powell, “Interest rates are still low by historical standards, and they remain just below the broad range of estimates of the level that would be neutral for the economy — that is, neither speeding up nor slowing down growth.” The Dow Jones Industrial Average surged 2.5 percent to close at 25,366.43, while the S&P 500 Index jumped 2.3 percent to close at 2,743.79. “Markets wanted to hear Powell say that there is no preset course of rates, that he is mindful of weaknesses in the global economy, and, most importantly, that tariffs have altered the calculus of the future of the U.S. economy,” Cox said.